Atara Falls As PINTA Sinks In Phase II
This article was originally published in Scrip
Atara Biotherapeutics Inc. fell 36.8% to $21 per share on Dec. 14 after the company suspended work on PINTA 745 for the reversal of peptide-energy wasting (PEW), leaving only two of the company's Christopher Columbus-themed drug candidates – previously in development by subsidiaries known as Nina and Santa Maria – afloat along with newer oncology and immunotherapy programs.
You may also be interested in...
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.